Infliximab Real-World Studies: Induction and Maintenance

Studies in Crohn's Disease (CD) and Ulcerative Colitis (UC)22,45-52

Key Findings:

  • Demonstrated clinical efficacy22,45-52

 - Across 17 induction/maintenance studies evaluating more than 4,500 IBD patients

  • Demonstrated endoscopic efficacy46-48

 - Across 4 induction/maintenance studies evaluating more than 300 IBD patients

  • Demonstrated CRP improvements46,47

- Across 4 induction/maintenance studies evaluating more than 400 IBD patients

  • A comparable tolerability profile to Remicade®† 22,46,47

- Across 7 induction/maintenance studies evaluating more than 1,200 IBD patients

 

Quote on Systematic Review of Biosimilars in IBD

 Systematic review of biosimilars in IBD - Martelli L, Peyrin-Biroulet L. Curr Med Chem 201656.

 

Read About Switch Studies

Learn More About Paediatric Studies

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

†Remicade® is a registered trademark of MSD.

IBD, Inflammatory bowel disease; CRP, C-reactive protein.

 

 

PP-IFA-GBR-0307. December 2018